Actively Recruiting
Evaluating Vaginal Misoprostol for Improving Cervical Cancer Screening in Women with Type 3 Transformation Zone
Led by University of Alabama at Birmingham · Updated on 2026-08-31
420
Participants Needed
1
Research Sites
53 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a randomized controlled trial to evaluate the use of misoprostol in women undergoing cervical cancer screening who have a Type 3 transformation zone TZ. The study involves non-pregnant women aged 25 years or older and aims to see if misoprostol can change the TZ from Type 3 to Types 1 or 2, which may improve screening accuracy. This trial is led by the University of Alabama at Birmingham and uses a double-blind design with placebo control. Participants will receive either 600 mcg of misoprostol or a matching placebo, both given as three vaginal tablets at two time points 2 to 3 hours and again 4 to 6 hours before visual inspection with acetic acid VIA. This treatment schedule is designed to assess the conversion of the transformation zone during cervical cancer screening. The study compares the conversion rates at these two time intervals after administration. During the trial, participants will undergo VIA screening at the specified times after treatment. Researchers will measure the primary outcome of conversion rate from Type 3 to Types 1 or 2 TZ approximately 2 to 3 hours and 4 to 6 hours following drug administration. Secondary outcomes include comparing conversion rates between the two time points. Participants will be closely monitored throughout the screening process, and the total study duration extends through the planned completion date in 2028.
CONDITIONS
Brief Title
Use Misoprostol to Optimize Prevention of Cervical Cancer
Research Team
W
Warner K Huh, MD
S
Simon M Manga, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here